Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of PF-06342674 in Multiple Sclerosis
NCT02045732Phase 1Terminated
- Sponsor
- Pfizer
- Start
- Sep 2014
- Primary completion
- Oct 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of crebankitug in multiple sclerosis (MS) (5 arms), sponsored by Pfizer. Primary endpoints: Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), and Withdrawals Due to AEs at Day 127, Number of Treatment-Emergent AEs and SAEs by Severity at Day 127 and 4 more. Started Sep 2014; status: terminated.
02
Drugs
crebankitug
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02045732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02045732.